Waters Corporation has completed the previously announced combination with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company. The transaction forms a global life sciences and diagnostics leader, equipped with the best-in-class technologies and an industry-leading financial outlook. The company also announced the appointment of Claire M Fraser, PhD, to its Board of Directors, increasing the size of the Waters Board to a total of 11 members.

Dr Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr Fraser received a BS in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a PhD in Pharmacology from the State University of New York at Buffalo.

"As we reach this important milestone, I want to welcome our new colleagues to Waters and Dr Claire Fraser to our Board. Dr Fraser is an internationally recognised scientist with an extensive background in genomics, infectious diseases and molecular diagnostics. We will benefit from her expertise and deep knowledge of the business to help oversee our next era of growth and value creation," said Flemming Ørnskov, MD, MPH, Chairman, Waters.

With the transaction now closed, Waters has established four divisions that reflect the company's continued focus on high-volume testing in regulated applications and its decisive expansion into high-growth adjacent markets. The divisions bring together leading scientific teams to support the development and manufacturing of large and small molecule therapeutics and food and environmental testing, and to advance specialty diagnostics in attractive molecular, microbiology and multiplex applications.

"Our combination with BD's Biosciences and Diagnostic Solutions businesses marks a pivotal moment for Waters, bringing together world-class scientific expertise across chemistry, physics and biology, with rich histories of innovation. As we enter this next chapter, our focus is clear: address our customers' unmet needs, deliver long-term value for our shareholders, and provide solutions that advance global health. Through our category-defining products and shared culture of innovation, I am confident that together we will accelerate the benefits of pioneering science," said Udit Batra, PhD, President and Chief Executive Officer, Waters.